Orexo participating in new project concerning R&D for Drug Delivery technologies in collaboration with Uppsala University
Uppsala, Sweden - February 6, 2018 - Orexo is entering, together with some other companies, into collaboration with Uppsala University’s Faculty of Pharmacy. This initiative is the first in the drug delivery area and aims to create an arena where academia and industry meet to eventually become part of the leading research initiatives in the world to improve drugs and make them more effective.
The Swedish Drug Delivery Forum (SDDF), as the initiative is called, is Sweden’s first national project concerning drug delivery and drug formulation. With financial aid from Vinnova, research programs are being set up on three technological platforms, Parenteral, Oral and Pulmonary formulations. The initiative will lead to new drugs and improved treatments with drugs which will benefit both patients and the healthcare service.
– We primarily hope to deliver advanced research and to train researchers in the drug delivery area, but also anticipate that we will open strategic doors for collaboration, networking and mobility between academia and industry, says Göran Alderborn, Professor at the Faculty of Phamacy at Uppsala University.
– We are delighted to be part of this unique project in the drug delivery area, which is the foundation of Orexo’s business. With our long experience and competence in the field, we hope to be able to make a positive contribution to this project, at the same time as it can give both inspiration and knowledge in our work of developing new products, comments Robert Rönn, Head of Pharmaceutical Development and IP at Orexo AB.
For more information please contact, [email protected]
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees was approx. 100. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com.
 Other companies that are a part of this collaboration are Affibody, Apotek Produktion & Laboratorier, AstraZeneca, Clinical Trial Consultants, Disruptive Materials, Ferring (DK), Nanologica, Recipharm Pharm Dev and XSpray Microparticles